Nektar Therapeutics buy Piper Sandler
Start price
04.11.24
/
50%
€1.25
Target price
04.11.25
€6.42
Performance (%)
-53.40%
End price
05.11.25
-
Summary
This prediction is currently being closed. The BUY prediction by Piper_Sandler for Nektar Therapeutics is performing very badly with a performance of -53.40%. Piper_Sandler has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | - | - | - |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% |
Comments by Piper_Sandler for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $7.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat
In the thread Trading Nektar Therapeutics
Die von Piper_Sandler gewählte maximale Laufzeit wurde überschritten